Affiliation:
1. Department of Pharmacy Duke University Medical Center Durham North Carolina USA
2. Department of Pharmacy University of North Carolina Medical Center Chapel Hill North Carolina USA
3. Division of Cardiology University of North Carolina Medical Center Chapel Hill North Carolina USA
Abstract
AbstractBackgroundWe conducted a single‐center, retrospective comparison of adult patients who received warfarin and ASA or warfarin alone after HeartMate 3 (HM3) LVAD placement.MethodsThe primary outcome was a composite of bleeding and thrombotic events.ResultsOf 81 patients, 53 patients received warfarin and ASA, and 28 patients received warfarin alone. A primary outcome event occurred in 22 of 53 patients (41.4%) in the warfarin and ASA group and in 2 of 28 patients (7.1%) in the warfarin alone group (p = 0.0533). The odds of a bleeding event occurring were higher in the warfarin and ASA group (32.1% vs. 7.1%, p = 0.01309). The odds of a thrombotic event occurring were not significantly different between the warfarin and ASA group and the warfarin alone group (9.4% vs. 0%, respectively, p = 0.1582).ConclusionThe complete omission of ASA from the antithrombotic regimen of patients with a HM3 LVAD was associated with less bleeding events without an increase in thrombotic events.
Subject
Biomedical Engineering,General Medicine,Biomaterials,Medicine (miscellaneous),Bioengineering
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献